{
    "2020-04-09": [
        [
            {
                "time": "",
                "original_text": "【健帆生物|预告点评】20年Q1业绩大幅超预期，行业认可度与渗透率不断提升【安信医药马帅团队】",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "20年Q1",
                        "业绩",
                        "超预期",
                        "行业认可度",
                        "渗透率"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "A股异动 | 健帆生物涨逾6% 料一季度净利同比增30%至50%",
                "features": {
                    "keywords": [
                        "A股",
                        "健帆生物",
                        "涨逾6%",
                        "一季度",
                        "净利",
                        "同比增30%至50%"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}